FedCirc voids Seagen patent in $41m cancer treatment dispute

The appeals court reversed a jury verdict, finding the antibody-drug conjugate patent lacked adequate written description and enablement support from its priority application.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

USPTO hands win to Daiichi Sankyo in cancer drug dispute

18 January 2024 The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals.

Generics

Daiichi Sankyo secures nearly $46m legal fees in antibody arbitration

30 November 2023 Final award follows and incorporates the August 2022 decision by the arbitrator denying all claims levied at the Japanese company | Dispute involves antibody drug conjugate technology.

Americas

Texas court awards $41m to US biotech

21 July 2022 Japan-based pharma company must pay for infringment | Drug was recently approved for breast cancer treatment by EU.